



BIOVAXYS ANNOUNCES SHAREHOLDER MEETING RESULTS

VANCOUVER, BC, August 16, 2024 - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“**BioVaxys**” or the “**Company**”) is pleased to announce the results of its Annual General Meeting of shareholders held Thursday, August 15, 2024 (the “**Meeting**”). All matters presented to the shareholders of the Company (the “**Shareholders**”) as set out in the Management Information Circular of Company dated June 27, 2024, were approved at the Meeting.

Shareholders approved the setting of the number of directors at three (3) and the election of James Passin, Anthony Dutton, and Craig Loverock as directors of the Company for the ensuing year. Shareholders also appointed Dale Matheson Carr-Hilton LaBonte LLP, Chartered Professional Accountants, as the Company’s auditor and authorized the board of directors of the Company to fix the remuneration to be paid to the auditor.

James Passin, Chief Executive Officer and Director of the Company, commented, “We are pleased to see that over 45.5% of our Shareholders participated in voting at the Meeting. In addition, to obtain an approval rating of over 99% demonstrates that Shareholders support the Company’s vision. We wish to thank Shareholders for their continued support of the Company.”

On other matters, the Company wishes to issue a correction to its news release dated August 2, 2024, in which the Company disclosed the closing of the second tranche (the “**Second Tranche**”) of its previously announced private placement. The Company had advised that the Second Tranche had consisted of the issuance of 2,762,340 units of the Company at a price of \$0.05 per unit for aggregate gross proceeds of \$138,117, and the issuance of 800,000 shares (the “**Debt Settlement Shares**”) at a deemed value of \$0.05 per Debt Settlement Share to satisfy an aggregate of \$40,000 in bona fide debt.

The Company clarifies that the Second Tranche comprised the issuance of 4,212,340 units of the Company (the “**Units**”, and each, a “**Unit**”) at a price of \$0.05 per Unit for aggregate gross proceeds of \$210,617 and the Debt Settlement Shares. In connection with the closing of the Second Tranche, the Company paid cash finder’s fees in the aggregate of \$4,800 and issued a total of 96,000 finder’s warrants. All other details including, but not limited to, the description of each Unit, exercise terms of convertible securities, use of net proceeds, and applicable hold periods, as provided in the news release dated August 2, 2024, remain unchanged.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and its HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic

vaccine using its' proprietary HapTenix© 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology knowhow and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the Canadian Securities Exchange under the stock symbol "BIOV", on the Frankfurt Bourse (FRA: 5LB), and quoted in the US on the OTC Markets (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed "James Passin"

James Passin, Chief Executive Officer

Phone: +1 646 452 7054

Cautionary Statements Regarding Forward Looking Information

The Canadian Securities Exchange ("CSE") has neither approved nor disapproved the contents of this press release. The CSE does not accept responsibility for the adequacy or accuracy of this release. This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.